Abstract-A peptide containing only 4 amino acid residues (KRES) that is too small to form an amphipathic helix, reduced lipoprotein lipid hydroperoxides (LOOH), increased paraoxonase activity, increased plasma HDL-cholesterol levels, rendered HDL antiinflammatory, and reduced atherosclerosis in apoE null mice. KRES was orally effective when synthesized from either L or D-amino acids suggesting that peptide-protein interactions were not required. Remarkably, changing the order of 2 amino acids (from KRES to KERS) resulted in the loss of all biologic activity. Solubility in ethyl acetate and interaction with lipids, as determined by differential scanning calorimetry, indicated significant differences between KRES and KERS. Negative stain electron microscopy showed that KRES formed organized peptide-lipid structures whereas KERS did not. Another tetrapeptide FREL shared many of the physical-chemical properties of KRES and was biologically active in mice and monkeys when synthesized from either L-or D-amino acids. After oral administration KRES and FREL were found associated with HDL whereas KERS was not. 
T here has been a long search for peptides smaller than apolipoprotein A-I (apoA-I), but with many of the properties of apoA-I. This search initially led to the synthesis of the peptide 18A. 1 18A does not have sequence homology to apoA-I but forms a class A amphipathic helix similar to those found in apoA-I with some of the same lipid binding properties. 2 Addition of terminal blocking groups (Ac-18A-NH 2 ) resulted in increased lipid affinity. 3 However, Ac-18A-NH 2 was relatively weak in preventing LDL-induced monocyte chemotactic activity (MCA) in human artery wall cell cultures and failed to inhibit diet-induced atherosclerosis in mice. 4 A series of peptides with increasing phenylalanine residues on the hydrophobic domain were synthesized and 4F was found to be most ideal based on solubility, lipid binding, and biologic activity. 4 In addition to its ability to bind cholesterol and phospholipids, apoA-I was found to bind lipid hydroperoxides (LOOH). 5 Circulating LDL always contains a small amount of LOOH. 5 When freshly isolated LDL is added to human artery wall cocultures, it is trapped in the subendothelial space and additional LOOH produced by the cells partition into the trapped LDL. 5, 6 When a critical threshold of LOOH within the trapped LDL is reached, arachidonic acidcontaining phospholipids in the LDL are oxidized and cause the artery wall cells to produce MCA. 5, 6 When human apoA-I was added to human artery wall cocultures in preincubation and removed before the addition of LDL, there was a marked reduction in LDL-induced MCA. However, when human apoA-I was added to the cocultures with the LDL (a coincubation) there was no reduction in LDL-induced MCA 6 indicating that human apoA-I bound LOOH in a manner that allowed the formation of oxidized phospholipids unless the apoA-I-LOOH complex was removed. 6 In contrast some of the peptide mimetics of apoA-I inhibited LDL-induced MCA even in a coincubation, suggesting that the mimetics more effectively sequestered LOOH. 4 Oral L-4F (4F synthesized from L-amino acids) was rapidly degraded by proteolytic enzymes and was not biologically active. 7 Oral D-4F (4F synthesized from all D-amino acids) was not degraded and dramatically reduced atheroscle-rosis in mice. 7 Subsequent studies demonstrated that D-4F associates with HDL, reduces LOOH, increases the HDL associated enzyme paraoxonase (PON), enhances the formation of pre-␤ HDL and increases reverse cholesterol transport from macrophages. 8 A 10 amino acid sequence from apoJ synthesized from all D-amino acids D-[113-122]apoJ was also recently shown to be able to associate with HDL after an oral dose, reduce LOOH, increase PON activity, render HDL antiinflammatory in mice and monkeys, and dramatically reduce atherosclerosis in apoE null mice without increasing the formation of pre-␤ HDL. 9 Both 4F and D- [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] apoJ are predicted by the LOCATE program 10 to contain amphipathic helixes (a class A amphipathic helix for D-4F and a class G* amphipathic helix for D-[113-122]apoJ). We asked if the ability to associate with HDL, remove LOOH, increase PON activity, render HDL antiinflammatory, and reduce atherosclerosis in mouse models, requires the formation of an amphipathic helix? To test this question we designed small peptides that have amphipathic properties but which are predicted by the LOCATE program to be too small to form an amphipathic helix.
Materials and Methods

Materials
Protected amino acid derivatives, chlorotrityl resin, and condensing reagents were from Nova Biochem, Calif, 14 C-labeled amino acids were from American Radiolabeled Chemicals (St Louis, Mo), other materials were from previously identified sources. 8, 9, [11] [12] [13] [14] 
Synthesis of Peptides
Peptides were synthesized by a combination of solid-phase and solution-phase methods, 15, 16 which are detailed in the online data supplement available at http://circres.ahajournals.org.
Animals
ApoE null female mice on a C57BL/6J background were purchased from Jackson Laboratory (Bar Harbor, Me) and maintained on a chow diet (Ralston Purina). Cynomolgous monkeys were from a colony at UCLA. The UCLA Animal Research Committee approved all animal studies.
Plasma Lipoproteins, Artery Wall Cell Cultures, Monocyte Chemotaxis
Lipoproteins, artery wall cell cultures, and monocytes were prepared and determination of MCA was as described previously 8 using human (after informed consent) or mouse blood. Plasma was fractionated by FPLC as previously described. 8 
Quantifying Atherosclerotic Lesions
Aortic root sinus sections and en face aortic preparations were prepared and analyzed as previously described. 7, 17 
Solubility of Peptides in Ethyl Acetate
Peptides were weighed into centrifuge tubes and ethyl acetate (HPLC grade; residue after evaporation Ͻ0.0001%) added to give a concentration of 10 mg/mL. Tubes were sealed and kept at room temperature for 30 minutes with vortexing every 10 minutes followed by centrifugation for 5 minutes at 10 000 rpm and the supernatant removed to a previously weighed tube. Ethyl acetate was evaporated under argon and the tubes weighed to determine the amount of peptide in the supernatant.
Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) was performed as described 4, 12, 13 and further detailed in the online data supplement.
Other Procedures
Determination of cholesterol, PON activity, lipoprotein-LOOH concentrations, Western analyses, and 2D agarose/native PAGE were as described previously, 8 as was the measurement of reverse cholesterol transport from macrophages in vivo. 8, 18 Interaction of peptides with DMPC 4 and negative stain electron microscopy 19 were performed as described. Statistical significance was determined by use of model I ANOVA or nonpaired t-test, and significance was defined as a value of PϽ0.05.
Results
Adding KRES to human artery wall cocultures in a preincubation (but not a coincubation) significantly inhibited LDLinduced MCA (data not shown).
Modifying KRES by substitution of aspartic acid for glutamic acid (ie, KRDS) resulted in a peptide with Ͻ10% of the activity of KRES (data not shown).
Administering 200 g of KRES synthesized from all L-amino acids by gastric gavage, or administering the same amount of peptide in mouse chow rendered HDL antiinflammatory (ie, the HDL from mice that received KRES significantly inhibited LDL-induced MCA) ( Figure 1A D-KRES but not D-KERS significantly reduced aortic root sinus atherosclerosis ( Figure 3A ) and aortic atherosclerosis in en face preparations ( Figure 3B ). The peptides constituted only 0.02% by weight of the diet. There was no significant difference in water or food consumption, body weight, liver weight, and heart weight, and there was no difference in liver function (alkaline phosphatase, AST, ALT, total or conjugated bilirubin, or albumin) or renal Figure 1 . A, Three-monthold apoE null mice (nϭ4 per group) were given by gastric gavage water alone or 200 g of KRES (synthesized from L-amino acids) or mouse chow alone or 200 g of KRES in the same amount of mouse chow that was consumed overnight. The mice were bled 4 hours after gavage or after eating the chow overnight and HDL was isolated by FPLC. No additions (No Addition) or a control human LDL at 100 g/mL LDL-cholesterol alone (LDL), or LDL at 100 g/mL LDL-cholesterol together with a control human HDL at 50 g/mL HDL-cholesterol (LDL ϩ hHDL), or LDL at 100 g/mL LDL-cholesterol together with mouse HDL at 50 g/mL HDL-cholesterol from mice that did not receive peptide (LDL ϩ No Peptide mHDL) or from mice that did receive peptide (LDL ϩ KRES mHDL) were added to humanartery wall cells. After 8 hours of incubation the media were removed and assayed for MCA. The results shown are the MeanϮSD of quadruplicate determinations with 9 fields counted in each determination. *PϽ0.0001 for LDL compared with no addition or compared with LDL ϩ hHDL; **PϽ0.0001 compared with LDL ϩ No Peptide mHDL by gastric gavage; ***PϽ0.0001 compared with LDL ϩ No Peptide mHDL Powdered diet. B, ApoE null mice 8 weeks of age were given no peptide (CHOW) (nϭ21) or D-KERS (nϭ21) or D-KRES (nϭ21) at 200 g/gram chow. The mice consumed Ϸ2.5 g of chow per day per mouse and there was no difference between groups. After 15 weeks the mice were euthanized. The ability of their HDL to inhibit LDL-induced MCA was determined as described in Panel A. The data shown are the MeanϮSD of quadruplicate determinations with 9 fields counted in each determination. *PϽ0.0001 for LDL compared with no addition or compared with LDL ϩ hHDL; **PϽ0.0001 compared with Chow mHDL and also compared with ϩD-KERS mHDL. C, Human LDL (hLDL) or mouse LDL (mLDL) at 100 g/mL LDL-cholesterol from the mice described in Panel B was added to the cultures and assayed as in Panel A. The values shown are MeanϮSD for quadruplicate determinations with nine fields counted in each determination. *PϽ0.0001 hLDL compared with No Addition; **PϽ0.001 compared with Chow mLDL. D, Plasma from 6-month-old female apoE null mice (1 mL) was incubated with L-KERS or L-KRES or D-KERS or D-KRES at the concentration shown on the X-axis for 60 minutes at 37°C with gentle mixing. The plasma was fractionated by FPLC and the lipid hydroperoxide (LOOH) content of the HDL-containing fractions determined as in Materials and Methods. *PϽ0.01 for L-KRES 5 g/mL compared with no peptide or L-KERS 10 g/mL; *PϽ0.001 for L-KRES 5 g/mL compared with L-KERS 5 g/mL; **PϽ0.001 for L-KRES 10 g/mL compared with no peptide or compared with L-KERS 5 or 10 g/mL; ***PϽ0.001 for D-KRES 5 g/mL compared with no peptide, or compared with D-KERS 5 or 10 g/mL; ****PϽ0.001 for D-KRES 10 g/mL compared with no peptide, or compared with D-KERS 5 or 10 g/mL. E, The LOOH content of the LDL-containing fractions described in Panel D was determined. *PϽ0.001 for L-KRES 5 g/mL compared with no peptide or L-KERS 5 or 10 g/mL; **PϽ0.001 for L-KRES 10 g/mL compared with no peptide or compared with L-KERS 5 or 10 g/mL; ***PϽ0.001 for D-KRES 5 g/mL compared with no peptide, or compared with D-KERS 5 or 10 g/mL; ****PϽ0.001 for D-KRES 10 g/mL compared with no peptide, or compared with D-KERS 5 or 10 g/mL. F, The PON activity of the HDL fractions described in Panel D was determined. *PϽ0.01 for L-KRES 5 g/mL compared with no peptide; *PϽ0.05 for L-KRES 5 g/mL compared with L-KERS 5 g/mL; *PϽ0.001 for L-KRES 5 g/mL compared with L-KERS 10 g/mL; ** PϽ0.001 for L-KRES 10 g/mL compared with no peptide or compared with L-KERS 5 or 10 g/mL; *** PϽ0.001 for D-KRES 5 g/mL compared with no peptide; *** PϽ0.01 for D-KRES 5 g/mL compared with D-KERS 5 or 10 g/mL; ****PϽ0.001 for D-KRES 10 g/mL compared with no peptide or D-KERS 5 or 10 g/mL.
function (creatinine) between groups (data not shown). D-KRES significantly raised HDL-cholesterol levels by 27% without significantly altering total plasma cholesterol or triglycerides (Table) . D-KRES did not significantly increase the formation of apoA-I with pre-␤ mobility nor did D-KRES enhance reverse cholesterol from macrophages (data not shown).
KRES is a zwitterionic tetrapeptide with amphipathic properties that is too small to form an amphipathic helix. However, as shown above, it associates with HDL after an oral dose and in vitro reduces LOOH and increases PON activity and it reduces atherosclerosis in apoE null mice. Another zwitterionic tetrapeptide with amphipathic properties that is too small to form an amphipathic helix is FREL. The addition of L-FREL to apoE null mouse plasma in vitro reduced LOOH in HDL ( Figure 4A ) and in LDL ( Figure 4B ), and increased PON activity ( Figure 4C ) similar to the action of KRES (Figure 1D through 1F) . Two hours after oral administration of L-FREL to apoE null mice the peptide was only associated with HDL and was still detectable in HDL after 48 hours ( Figure 4D ). The results with L-FREL differed from those of L-KRES in that L-FREL did not significantly associate with small particles to the far right of HDL, as was the case for L-KRES (compare Figure  2A and 4D) .
FREL administered orally to apoE null mice for 12 weeks significantly decreased LOOH ( Figure 4E ), increased PON activity ( Figure 4F ), rendered HDL antiinflammatory ( Figure  4G ), decreased LDL-induced MCA ( Figure 4H ), and decreased aortic root sinus lesion area ( Figure 4I) . Although there was a trend toward decreased en face lesion area in mice treated with L-KRES or D-FREL (data not shown), a statistically significant decrease was only seen with L-FREL ( Figure 4J ). L-FREL and L-KRES significantly increased HDL-cholesterol without significantly changing total plasma cholesterol or triglycerides (Table) .
Based on the data presented above we hypothesized that the interaction with lipids of KRES and FREL would be similar and different from that of KERS. As shown in Figure  5A KRES and FREL were readily soluble in ethyl acetate whereas KERS was not.
Figure 5B shows that in the absence of added peptide, DMPC formed monotonous vesicles of 12.5 to 14 nm in diameter, which were not altered by the addition of KERS suggesting that Plasma from 6-month-old female apoE null mice (1 mL) was incubated with L-FREL at the concentration shown on the X-axis for 60 minutes at 37°C with gentle mixing. The plasma was fractionated by FPLC and the lipid hydroperoxide (LOOH) content of the HDL-containing fractions determined as in Methods.*PϽ0.01 for L-FREL 1.0 g/mL compared with zero; *PϽ0.05 for L-FREL 1.0 g/mL compared with 10 g/mL; **PϽ0.001 for L-FREL 5 g/mL compared with zero; **PϽ0.01 for L-FREL 5 g/mL compared with 0.5 g/mL; ***PϽ0.001 for L-FREL 10 g/mL compared with zero or L-FREL 0.5 g/mL; ***PϽ0.05 for L-FREL 10 g/mL compared with 1.0 g/mL. Panel B. The LOOH content of the LDL-containing fractions described in Panel A was determined. * PϽ0.01 for L-FREL 5 g/mL compared with zero; *PϽ0.05 for L-FREL 5 g/mL compared with 0.5 g/mL and 10 g/mL; **PϽ0.001 for L-FREL 10 g/mL compared with 0 or to 0.5 or 1.0 g/mL. Panel C. The PON activity of the HDL fractions described in Panel A was determined. * PϽ0.05 for L-FREL 1.0 g/mL compared with zero;*PϽ0.01 for L-FREL 1.0 g/mL compared with 5.0 g/mL; *PϽ0.001 for L-FREL 1.0 g/mL compared with 0.5 or 10 g/mL; **PϽ0.001 for L-FREL 5.0 g/mL compared with zero or 0.5 g/mL; **PϽ0.01 for L-FREL 5.0 g/mL compared with 1.0 or 10 g/mL; ***PϽ0.001 for L-FREL 10 g/mL compared with zero or 0.5 or 1.0 g/mL. D, In each of 2 separate experiments, 5 groups of 4-month-old female apo E null mice (nϭ4 for each group) were given by stomach tube, 100 g of 14 C-L-FREL with 1ϫ10 6 DPM per mouse in 100 L of saline and blood was obtained at 2, 6, 24, 48, and 72 hours following the dose. Two hundred microliters of pooled plasma was fractionated by FPLC and the cholesterol and 14 C-contents of the fractions were determined. The results shown are the average value for each fraction from the 2 separate experiments (ie, total of 8 mice per time point).
KERS did not interact with the DMPC. In contrast, the addition of KRES to DMPC caused the formation of stacked lipidpeptide bilayers with a bilayer dimension of 3.4 to 4.1 nm with the spacing between the bilayers of Ϸ2 nm ( Figure 5C ). KRES also caused the formation of peptide-lipid complexes with a diameter of 7.5 nm ( Figure 5C ). Not shown, KRES also caused the formation of peptide-lipid complexes with a diameter of 38 nm. Figure 5D demonstrates that the addition of FREL to DMPC caused the formation of stacked lipid-peptide bilayers similar to those formed by KRES.
KRES reduced the highly cooperative gel to liquid-crystalline phase transition of DMPC multilamelar vesicles to a significantly larger extent than did KERS ( Figure 5E ). Thus, KRES interacts more avidly with DMPC to change DMPC phase transition properties. These results are in agreement with the results obtained by negative stain electron microscopy.
To determine whether these tetrapeptides were active in another species, we administered FREL to monkeys. Oral FREL significantly reduced LOOH and rendered monkey HDL antiinflammatory ( Figure 6 ).
Discussion
Our previous studies 5, 6 indicated that the ability of apoA-I to modulate inflammatory processes relates in part to its ability to bind and remove inflammatory lipids. 20 Because all peptides to date with these properties (4F, 5F, D-[113-122]apoJ) have the potential to form an amphipathic helix, we asked if the formation of a helix was required.
Preliminary studies with molecular modeling suggested that KRES is zwitterionic with segregated polar and nonpolar faces consistent with an amphipathic molecule, which could not form a helix because of its small size (data not shown). KRES was active in vitro and in vivo in apoE null mice regardless of whether it was synthesized from L-or from D-amino acids strongly suggesting that its activity was not dependent on peptide-protein interactions. Reversing the order of the 2 middle amino acids yielded KERS, which was biologically inactive. Preliminary molecular modeling of KERS also showed it to be zwitterionic with segregation of polar and nonpolar faces consistent with an amphipathic molecule, which could not form a helix because of its small size (data not shown).
Both KRES and KERS are soluble in water as would be expected for peptides that are zwitterionic (data not shown) but solubility in ethyl acetate was dramatically different between KRES and KERS ( Figure 5A ). KRES formed peptide-lipid structures with DMPC, which were not formed by KERS ( Figure 5B and 5C), and DSC confirmed that KRES interacted more avidly with DMPC than KERS ( Figure 5E ).
In vitro, KRES reduced LOOH ( Figure 1D and 1E) and increased PON activity ( Figure 1F ). In vivo, there were substantial differences in the plasma distribution of the 2 peptides after an oral dose (Figure 2 ). KRES associated with HDL but KERS did not.
Another tetrapeptide, FREL, was also readily soluble in ethyl acetate ( Figure 5A ) and formed structures similar to KRES with DMPC ( Figure 5D ). Similar to KRES (and different from KERS) FREL reduced LOOH and increased PON activity in vitro ( Figure 4A through 4C) . Similar to KRES (and different from KERS), FREL associated with HDL after an oral dose, but FREL was only associated with HDL ( Figure 4D ) whereas KRES was also associated with fractions far to the right of HDL in the FPLC chromatogram (Figure 2 ). Similar to KRES (and different from KERS) ( Figure 3A and 3B) FREL inhibited atherosclerosis in apoE null mice ( Figure 4I and 4J) . Therefore, the interaction of the peptides with lipids in vitro predicted their biologic activity in vivo.
Residues 39 to 42 of human lactorferrin are KRDS. The addition of hydrophobic alkyl groups to the terminal ends of KRDS synthesized from all L-amino acids yielded a peptide known as PEP 1261, which inhibited platelet aggregation in Figure 5 . Panel A. The solubility of the three peptides in ethyl acetate was determined as described in Materials and Methods. The values shown are the MeanϮSD Control refers to ethyl acetate that was sham treated (ie, no peptides were added). *PϽ0.001 FREL compared with control or FREL compared with KERS or FREL compared with KRES; **PϽ0.001 KRES compared with control or KRES compared with KERS. The comparison of KERS to control was not significant. B and C, To 1 mg/mL of DMPC suspension in PBS was added 10% deoxycholate until the DMPC was dissolved. KERS (Panel B) or KRES (Panel C) were or were not added (DMPC: peptide; 1:10; wt:wt) and the reaction mixture dialyzed B, In the absence of added peptide DMPC formed vesicles of 12.5 to 14 nm in diameter, which were not altered by the addition of KERS. The figure is an electron micrograph prepared with negative staining and shown at 147 420ϫ magnification. C, The green arrow (on the left) indicates peptide-lipid complexes measuring 7.5 nm (they appear as clusters of peptide-lipid complexes), which were seen after addition of KRES. Additionally, KRES caused the formation of stacked lipid-peptide bilayers as indicated by the red arrow (on the right) with a bilayer dimension of 3.4 to 4.1 nm and spacing between the bilayers (black lines between white lines in the stack of disks) of approximately 2 nm. The conditions and magnifications are the same as described in Panel B. D, FREL was added to DMPC as described above except that the ratio of DMPC: peptide was 2.5: 1.0; (w:w), deoxycholate was not added, and instead the mixture was heated to 50°C and then cooled to room temperature for six cycles and the magnification is 289,008x. Panel E. Differential scanning calorimetry experiments reveal that KRES interacts more avidly with DMPC to decrease the DMPC phase transition compared with KERS.
vitro. 21 Injection of PEP 1261 intraperitoneally in 10% DMSO at a dose of 10 mg/kg/d reduced adjuvant induced arthritis in rats. 22 In our hands this peptide was only weakly active in vitro in inhibiting LDL-induced MCA compared with KRES (data not shown).
The increase in PON activity in vitro by KRES ( Figure 1F ) and FREL ( Figure 4C ) was associated with a decrease in LOOH ( Figure 1D and 1E, 4A and 4B) and likely reflects the activation of HDL enzymes as a result of the removal of inhibitory oxidized lipids. 23 Based on our previously published work, 5, 6, 8, 20 the reduced ability of LDL to induce MCA, and the improved antiinflammatory properties of HDL after oral administration of KRES or FREL is consistent with the removal of LOOH from LDL and HDL and the activation of HDL-associated antioxidant enzymes.
The reduction in lesions with KRES and FREL was less dramatic than that seen 7 with D-4F or D-[113-122]apoJ. 9 The difference in apparent potency may have multiple causes. D-4F and D-[113-122]apoJ effectively sequester inflammatory lipids such that they inhibit LDL-induced MCA in both a preincubation and a coincubation. 4 -6,9 The tetrapeptides were active only in a preincubation but not in a coincubation (data not shown) indicating a relative decreased ability to sequester inflammatory lipids.
Also unlike D-4F, the tetrapeptides did not increase the formation of pre-␤ HDL or enhance reverse cholesterol transport from macrophages in apoE null mice (data not shown) despite causing a significant increase in plasma HDL-cholesterol (Table) .
Regardless of the relative potency of the tetrapeptides compared with the larger helix forming peptides, the studies presented here demonstrate that peptides which are too small to form amphipathic helixes can still bind lipids, associate with HDL, reduce LOOH, and increase PON activity and that these properties result in antiinflammatory activity in both mice and monkeys. Figure 6 . Under conscious sedation (ketamine 10 mg/kg, IM) 2 female (Ϸ4 Kg) and 2 male (Ϸ4 Kg) Cynomolgous monkeys were each given by gastric gavage 25 mg of FREL (synthesized from L-amino acids) in 2.0 mL of water followed by 2.0 mL of water. Two mL of blood was obtained before administration of the peptide (Time 0) and 4.5 hours after administration of the peptide. A, HDL-LOOH content. *PϽ0.0001. B, LDL-LOOH content. *PϽ0.016. C, Ability of monkey HDL (mHDL) to inhibit human LDL (hLDL)-induced MCA was determined. The concentrations of the lipoproteins were as described for Figure 4G except that monkey HDL was used. The values represent the MeanϮSD for 4 monkeys with each monkey's sample assayed in quadruplicate with 9 fields counted for each replicate for each time point. *PϽ0.001 hLDL compared with No Addition; **PϽ0.01 hLDL ϩ hHDL compared with hLDL; ***PϽ0.001 hLDL ϩ mHDL 4.5 hours after FREL compared with hLDL ϩ mHDL Time 0.
